Function and repair
TB-500 and muscle recovery
I give strength measurements priority when somebody promises recovery. The mouse experiment puts the repair story through that harder test.
Fresh fibers, unchanged strength
The Spurney study of dystrophin-deficient mdx mice examined skeletal and cardiac muscle after chronic full-length thymosin beta-4. The animals received 150 micrograms intraperitoneally twice weekly for six months. Regenerating skeletal-muscle fibers increased significantly. Muscle strength and systolic cardiac function showed no significant improvement, while skeletal and cardiac fibrosis remained elevated.
This result earns its prominence by asking whether the repaired-looking tissue worked better. Counting fresh fibers gives one answer; measuring strength gives another. Both measurements deserve room in the same account. A recovery claim that mentions only regeneration has omitted function, the endpoint I value most.
These mice had dystrophin deficiency. Their disease model cannot stand in for an ordinary human muscle tear, and the experiment used the parent protein. Its value is narrower and more durable: it demonstrates how a promising tissue measurement can coexist with a disappointing functional result.
How access is structured
The prescription channel, and what it does not settle
TB-500 with laboratory-use labels is still sold for research, outside a patient-specific prescription pathway. Prescribing has begun for Wolverine (a TB-500 and BPC-157 blend) at Promise Peptides (mypromise.com); prescription-only care there puts each patient's case before a clinician licensed in the U.S. for a decision. Requests can be refused, and only U.S. patients can be considered; the state and treatment determine which options are offered. A compounded Wolverine medication has no FDA approval. Noting that the channel exists settles none of the argument above. The fragment still has no completed controlled human trial, the null result on muscle strength still stands, and the tumour and angiogenesis signal remains the open safety question; FDA keeps TB-500 in its withdrawn-nomination table with the safety concerns still recorded, as the legal status page explains. A prescription changes who is accountable for the decision; it does not change the evidence.
Muscle repair cells and exercise
The biological rationale has substance. In mouse and cell work, injury-induced thymosin beta-4 attracted myoblasts toward damaged muscle. Myoblasts are muscle-forming cells. A separate human exercise study identified thymosin beta-4 as an exercise-responsive circulating factor, called an exerkine.
I like the connection to the body’s own response to exertion. It makes the research question intelligible. Neither observation measures recovery after administering the isolated TB-500 fragment to people. The decisive missing comparison is still human function after that particular exposure.
Tendon and ligament healing
The most directly relevant connective-tissue finding here is improved medial collateral ligament healing in rats given thymosin beta-4. It places a ligament, rather than a heart or a skin wound, under examination. Direct human tendon or ligament results for the TB-500 fragment remain absent.
The rat skin-wound paper supplies the often-repeated healing-speed figures: 42% greater re-epithelialization at four days and up to 61% at seven days versus saline. Skin resurfacing in rats is the measured outcome. A human tendon endpoint would give me grounds to discuss an injury-recovery timetable.
TB-500 and BPC-157
These names regularly travel together in recovery discussions. TB-500 carries the actin-binding LKKTETQ region of thymosin beta-4; BPC-157 is a separate synthetic peptide. The 2026 Sports Medicine review considers both among unapproved musculoskeletal peptides and describes favorable tissue-repair outcomes in animal models alongside scarce rigorous human safety data, potential for serious harm and limited regulatory oversight.
Combining the names supplies none of the missing human comparisons. There is no validated combination regimen in the record here. The study-amount ledger identifies what the thymosin beta-4 experiments actually administered; the safety inspection covers the concerns that recovery enthusiasm tends to leave in the margin.